Xeris Biopharma Holdings, Inc. (XERS) is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable therapies. The company’s innovative drug formulations eliminate the need for complex reconstitution, making them more convenient for patients and healthcare providers. Xeris’ portfolio includes treatments for diabetes, hypoglycemia, and endocrine disorders, with a growing pipeline targeting rare and chronic diseases.
The company’s proprietary XeriSol™ and XeriJect™ platforms enable more stable, room-temperature injectable medications, addressing critical needs in emergency care and long-term treatment. Xeris’ flagship product, Gvoke®, an auto-injector for severe hypoglycemia, has gained traction as an easy-to-administer alternative to traditional glucagon kits. Additionally, the company’s acquisition of Strongbridge Biopharma has expanded its portfolio in rare disease treatments.
With increasing demand for patient-friendly drug delivery solutions, Xeris is positioned for growth in both the endocrinology and rare disease markets. The company’s innovative approach to injectables, strong product pipeline, and expansion into additional therapeutic areas make it a key player in the evolving biopharma landscape. Visit Xeris Biopharma’s website for more details.
